Maggie L. Shaw

Out-of-pocket (OOP) spending for patients with heart failure with reduced ejection fraction rose in the event of a worsening heart failure event across the 4 phases of Medicare Part D coverage.

The study authors hope their findings inform future interventions whose goal is to minimize the comorbidity burden of adults with multiple sclerosis (MS), thereby improving their quality of life and ultimate health outcomes.

Results from 2 studies presented at this year’s European Hematology Association meeting demonstrate the long-term tolerability and efficacy of the Bruton tyrosine kinase inhibitor.

Compared with their peers receiving injectable treatments for their relapsing-remitting multiple sclerosis (RRMS), children who received newer disease-modifying therapies (DMTs) had improved scores on several measures of disease progression.

Progressive rehabilitation produced superior results among patients randomized to a 36-session program during or following hospitalization for acute decompensated heart failure vs those randomized to usual care.

This week marks the 40th anniversary of the CDC's June 5, 1981, Morbidity and Mortality Weekly Report describing rare instances of immunocompromised status among 5 homosexual men in Los Angeles. The American Journal of Managed Care® spoke recently with lead author Michael Gottlieb, MD, who was the first to describe what would come to be known as HIV and AIDS.

Data from the DAPA-HF trial and published literature show intermediate-level cost-effectiveness of dapagliflozin use among patients with heart failure with reduced ejection fraction (HFrEF).

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.

Between 2014 and 2018, annual diagnoses for HIV in an emergency department (ED) in Hamilton County, Ohio, more than doubled, from 20 to 42.

Mount Sinai research released today shows a possible link between excess pericardial fat and greater risk of heart failure, with implications for early intervention and prevention of heart disease.

Here is some of the latest news in diabetes from our sister publication Pharmacy Times®.

The latest coverage in the heart failure space from across MJH Life Sciences™.

Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.

May 18 is HIV Vaccine Awareness Day. Here we explore just a few of the many reasons why a vaccine that is effective at preventing the acquisition of HIV and at reducing the viral load in those currently living with HIV remains an elusive goal.

Rates of acute heart failure (AHF) have recently been rapidly increasing among elderly and super-elderly patients in Japan, and this study investigated rates of all-cause death and mode of death among this patient population.

These 4 studies were pegged as “ones to watch” during the American College of Cardiology (ACC) annual briefing on results for consumers. They will be presented in the opening session of late-breaking clinical trial results on day 1 of ACC.21.

Although knowledge is plentiful on disease state improvements for adult patients with multiple sclerosis (MS) following use of newer disease-modifying therapies, less is known about similar outcomes among patients with pediatric-onset MS (POMS).

Despite overall survival improvements among pediatric patients living with HIV, 20.5% are still lost to follow-up.

Compared with nonsmokers who did not have recent exposure to secondhand smoke, a 35% greater chance for heart failure was seen among those with recent exposure to the toxic fumes.

New research demonstrates that patients with multiple sclerosis (MS) who were asymptomatic for COVID-19 had lower antibody levels against SARS-CoV-2, its causative virus, due to having fewer B cells.

Because real-world data are lacking on disease-modifying treatment (DMT) prescribing patterns for patients with multiple sclerosis (MS), a team of investigators wanted to make sure these individuals were receiving adequate care.

Disproportionate rates of HIV and sexually transmitted infections (STIs) among Black women, who have a nearly 4 times higher enrollment rate in community supervision programs, underscores the need for culturally targeted HIV/STI interventions.

Right ventricular systolic function evaluated through VO2 max is a more accurate measure of functional capacity of persons with heart failure compared with left ventricular systolic function.

Findings from a new study out of Mount Sinai in New York show a small but rare chance of developing new-onset heart failure following hospitalization for COVID-19.

Risk of infection topped the list of concerns among patients with multiple sclerosis (MS) who altered their usual care routines during the COVID-19 pandemic.

A new approach to identifying and defining heart failure among patients with chronic obstructive pulmonary disease (COPD) involves combining information gleaned from reviewing their electronic medical records and examination charts.

In an abstract presented at this year’s American Academy of Neurology annual meeting, patients with multiple sclerosis (MS) taking ocrelizumab had less of an immune reaction to infection with SARS-CoV-2, the virus that causes COVID-19.

With persons living with HIV increasingly succumbing to age-related diseases, a group of investigators looked into the greater risk of coronary artery disease among these individuals.

Overweight and obese adults, whose body mass index trended upward in a recent UK study, had higher risk of heart failure, all-cause mortality, and cardiovascular disease–related mortality.

Compared with disease-modifying therapy (DMT), age, insurance status, and Hispanic ethnicity were shown to more accurately predict likelihood of COVID-19 and hospitalization from it among individuals with multiple sclerosis (MS).